Search
-
GSK signs agreement with the WHO to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries
Media
GSK today announced that it has signed an agreement with WHO to donate 50 million doses of its influenza vaccine.
https://www.gsk.com/en-gb/media/press-releases/gsk-signs-agreement-with-the-who-to-donate-50-million-doses-of-pandemic-h1n1-vaccine-for-distribution-to-developing-countries/
First published: 09 November 2009
-
GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B
Media
Designation underscores the unmet need for medicines that can achieve functional cure in patients with chronic hepatitis B (CHB)
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-fast-track-designation-for-bepirovirsen-in-chronic-hepatitis-b/
First published: 12 February 2024
-
ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine
Media
ViiV announced start of phase III study with a two-drug regimen of long-acting, injectable cabotegravir & rilpivirine in adults with HIV-1.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-starts-third-phase-iii-hiv-treatment-study-investigating-long-acting-two-drug-regimen-of-cabotegravir-plus-rilpivirine/
First published: 27 November 2017
-
Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV
Media
SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir compared to raltegravir over 48 weeks in treatment of HIV patients.
https://www.gsk.com/en-gb/media/press-releases/shionogi-viiv-healthcare-announces-initial-data-from-pivotal-phase-iii-study-of-dolutegravir-in-hiv/
First published: 02 April 2012
-
ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention
Media
ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb”.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-exclusive-licensing-agreement-with-the-national-institutes-of-health-for-investigational-bnab-with-potential-for-long-acting-hiv-treatment-and-prevention/
First published: 21 November 2019
-
ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment
Media
TANGO will seek to enrol approximately 550 adults with HIV-1, from clinical trial sites in North America, Europe, Australia, and Japan.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment/
First published: 08 February 2018
-
ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing
Media
ViiV Healthcare presents positive 48-week data from phase III study
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-48-week-data-from-phase-iii-study-showing-every-two-month-regimen-of-investigational-long-acting/
First published: 09 March 2020
-
GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen
Media
GSK plc and Arrowhead Pharmaceuticals Inc. today announced that they have reached an agreement with Janssen Pharmaceuticals, Inc.
https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-obtain-exclusive-license-for-jnj-3989/
First published: 31 October 2023
-
ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1
Media
ViiV Healthcare today announced initial results from the Phase IIIb/IV FLAMINGO (ING114915) study.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-data-from-phase-iiibiv-study-of-dolutegravir-vs-darunavir-in-treatment-naïve-adults-with-hiv-1/
First published: 12 September 2013
-
ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV
Media
Fostemsavir addresses a critical need for those with little to no treatment options left who are at risk of further disease progression
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-marketing-authorisation-for-rukobia-fostemsavir-a-first-in-class-attachment-inhibitor-in-combination-with-other-antiretrovirals/
First published: 08 February 2021